6-(丙-2-基氧基)吡啶-2-羧酸 | 1240597-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(丙-2-基氧基)吡啶-2-羧酸
• 英文名称: 6-(Propan-2-yloxy)pyridine-2-carboxylic acid
• 英文别名: 6-propan-2-yloxypyridine-2-carboxylic acid
• CAS: 1240597-20-9
• 化学式: C₉H₁₁NO₃
• mdl: MFCD16697757
• 分子量: 181.19
• InChiKey: JRSQAZFZVOWWTO-UHFFFAOYSA-N

物化性质

• 沸点：
  313.9±22.0 °C(Predicted)
• 密度：
  1.187±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
  申请人：BIOGEN MA INC.

  公开号：US20220089592A1

  公开（公告）日：2022-03-24

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

  这项发明涉及Imidazo[1,2-a]pyridinyl Derivatives的化合物（I′）或其药学上可接受的盐，其中所有变量如规范中所定义，能够调节IRAK4的活性。该发明进一步提供了一种制造该发明化合物的方法，以及它们在治疗中的方法。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理炎症性疾病、自身免疫疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和骨骼疾病等疾病或疾病的用途。
• NOVEL CASE OF RENIN INHIBITORS
  申请人：Wu Tom Yao-Hsiang

  公开号：US20100120859A1

  公开（公告）日：2010-05-13

  The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及基于哌啶的肾素抑制剂化合物，其具有羧酸盐或羧酸末端基团，并且它们在治疗心血管事件和肾功能不全方面的使用。
• 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDIN-DERIVATE ALS BLOCKER DER TASK-1 UND TASK-2 KANÄLE ZUR BEHANDLUNG VON SCHLAFBEDINGTEN ATEMSTÖRUNGEN
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3386979A1

  公开（公告）日：2018-10-17
• N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
  申请人：Liu Kevin

  公开号：US20070208026A1

  公开（公告）日：2007-09-06

  Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
• US8343968B2
  申请人：——

  公开号：US8343968B2

  公开（公告）日：2013-01-01